title: Budesonide versus prednisolone retention enemas in active distal ulcerative colitis.
abstract: METHODS
  Efficacy and safety of the topically acting glucocorticosteroid budesonide retention enema (2.3 mg/115 mL) were compared with prednisolone disodium phosphate enema (31.25 mg/125 mL) in patients with active distal ulcerative colitis. The study was a randomized, multicentre trial, with two parallel groups and single-blind to the investigator. One hundred patients with active ulcerative colitis, not reaching beyond the splenic flexure as determined by endoscopy, were treated for up to 8 weeks.
  
  
  RESULTS
  Forty-five patients were randomized to receive budesonide and 55 to prednisolone. Both treatment groups improved significantly in terms of endoscopic and histological scoring during the study, but there were no statistically significant differences between the two groups. Clinical remission, defined as no more than three daily bowel movements without blood and endoscopically non-inflamed mucosa, was achieved in 16% of the patients in the budesonide group after four weeks and in 24% in the prednisolone group (N.S.). After 8 weeks treatment the clinical remission rate in the groups had increased to 36% for budesonide and 47% for prednisolone (N.S.). Mean morning plasma cortisol levels were unchanged in the budesonide group, whereas they were significantly suppressed in the prednisolone group after 2, 4 and 8 weeks (P < 0.0001). Side effects were mild and rare in both groups.
  
  
  CONCLUSIONS
  Treatment with budesonide enema in active distal ulcerative colitis was comparable, regarding efficacy, to treatment with conventional prednisolone enema. A prolongation of the treatment time from 4 to 8 weeks doubled the clinical remission rate in both groups. However, budesonide may be preferable to prednisolone since it causes less systemic effects as reflected by a lack of plasma cortisol suppression.
authors.affiliation: Unit of Gastroenterology and Hepatology, Karolinska Institute, Huddinge University Hospital, Sweden.
authors.forename: R
authors.initials: R
authors.lastname: Löfberg
authors.forename: O
authors.initials: O
authors.lastname: Ostergaard Thomsen
authors.forename: E
authors.initials: E
authors.lastname: Langholz
authors.forename: R
authors.initials: R
authors.lastname: Schiöler
authors.forename: A
authors.initials: A
authors.lastname: Danielsson
authors.forename: O
authors.initials: O
authors.lastname: Suhr
authors.forename: H
authors.initials: H
authors.lastname: Graffner
authors.forename: L
authors.initials: L
authors.lastname: Påhlman
authors.forename: P
authors.initials: P
authors.lastname: Matzen
authors.forename: J F
authors.initials: JF
authors.lastname: Møller-Petersen
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D019819:Budesonide; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000473:pathology; D004724:Endoscopy; D004733:Enema; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D011282:Pregnenediones / Q000008:administration & dosage / Q000627:therapeutic use*; D012074:Remission Induction
chemical_list: D000893:Anti-Inflammatory Agents; D011282:Pregnenediones; D019819:Budesonide; D011239:Prednisolone; D006854:Hydrocortisone